The molecular etiology of follicular thyroid tumors is largely unknown, rendering the diagnostics of these tumors challenging. The somatic alterations present in these tumors apart from RAS gene mutations and PAX8/PPARG translocations are not well described. To evaluate the profile of somatic alteration in follicular thyroid tumors, a total of 82 thyroid tissue samples derived from 48 patients were subjected to targeted Illumina HiSeq next generation sequencing of 372 cancer-related genes. New somatic alterations were identified in oncogenes (MDM2, FLI1), transcription factors and repressors (MITF, FLI1, ZNF331), epigenetic enzymes (KMT2A, NSD1, NCOA1, NCOA2), and protein kinases (JAK3, CHEK2, ALK). Single nucleotide and large structural variants were most and least frequently identified, respectively. A novel translocation in DERL/COX6C was detected. Many somatic alterations in non-coding gene regions with high penetrance were observed. Thus, follicular thyroid tumor somatic alterations exhibit complex patterns. Most tumors contained distinct somatic alterations, suggesting previously unreported heterogeneity.
Introduction
Somatic mutations play an important role in the development of differentiated thyroid cancer. The BRAFV600E somatic mutation is a known poor prognostic factor in papillary thyroid cancer (PTC) (Elisei et al., 2012) . PTC is also known to harbor RAS gene mutations, which are primarily associated with an aggressive phenotype and poor prognosis in thyroid cancer (Garcia-Rostan et al., 2003) . More recent reports suggest that RAS mutations are predictive of low risk follicular-patterned thyroid tumors with very infrequent lymph node and distant metastases (Gupta et al., 2013) . RET/PTC gene rearrangement, another well described somatic alteration involved in PTC pathogenesis, was considered mutually exclusive with BRAF mutation (Soares et al., 2003) ; however, their co-occurrence was recently found in nearly 20% of PTC tumors (Guerra et al., 2014) . A retrospective examination of PTC somatic alteration profiling and its association with clinical outcomes shows that some initial findings might evolve over time.
The Cancer Genome Atlas (TCGA) has extensively studied papillary thyroid cancer, the most frequently occurring thyroid cancer (Cancer Genome Atlas Research Network, 2014) , confirming that BRAFV600E represents the most frequent somatic mutation in PTC, whereas mutation in other MAPK-associated genes (NRAS, KRAS, and HRAS) were less frequent. MAPK-related gene mutations were mutually exclusive. Other single-gene mutations were detected in 1e2% of patients and suggested as driver events in PTC etiology, underlining the importance of rare/infrequent mutations in tumor development. These heterogeneous genes included the translation-associated factor EIF1AX, DNA repair genes CHEK2 and PPM1D, epigenetic regulators MLL (KMT2A), MLL3 (KMT2C), ARID1B, and PI3K/AKT pathway genes PTEN, AKT1/2, and TERT promoter mutations, and rare tumor suppressor/checkpoint gene mutations including TP53, RB1, NF1, and MEN1 (Cancer Genome Atlas Research Network, 2014) .
Fine needle aspiration biopsy (FNAB) is the most frequently used diagnostic method for thyroid tumors, but is often inconclusive. Follicular thyroid adenoma (FTA) is a benign counterpart of follicular thyroid carcinoma (FTC); the shared morphology and molecular features make diagnostics challenging. Therefore, surgery is required to confirm the malignant potential of follicular-patterned thyroid tumors. FNAB molecular screening has great potential to reduce unnecessary surgeries (Ferraz et al., 2011; Xing et al., 2004) . RAS somatic mutations and PAX8/PPARG rearrangements have been considered as potential markers of malignancy, although they occur in both tumor types (Esapa et al., 1999; Marques et al., 2002) . Many medical institutions have made RAS mutation screening a standard procedure and benign tumors harboring these somatic mutations are followed more carefully than wild-type tumors (Fukahori et al., 2012) . Furthermore, recent studies suggest that FTA with NRAS codon 61 mutations may have inherent malignant potential (Fukahori et al., 2012) .
As the above mutations are not found in all FTC tumors and their role in FTC development is incompletely understood, the identification new rare somatic mutations might improve pre-surgical FTC diagnostics (Ferraz et al., 2011) . Next generation sequencing (NGS) allows for broad mutation screening and has been successfully applied in thyroid cancer (ThyroSeq) (Nikiforova et al., 2013) .
The aim of this study was to characterize new somatic alterations in follicular thyroid tumors to obtain a better understanding of tumor etiology and to facilitate tumor diagnostics. Here, we present the first characterization of somatic alterations in follicular thyroid tumors using a large cohort of patients, performed via highdepth NGS of relevant cancer-related genes. 
Materials and methods

Clinical material
Targeted NGS
DNA was isolated from the 82 freshly frozen thyroid tissue samples using a QIAamp DNA Kit (Qiagen, Hilden, Germany). DNA quantification was performed using a Qubit fluorometer (Life Technologies, Foster City, CA, USA). Quality of the isolated genomic DNA was confirmed with a Bioanalyzer 2100 instrument using the Agilent DNA 1000 Kit (Agilent Technologies, Inc., Santa Clara, CA, USA). Subsequently, 1 mg DNA was fragmented via M-220 Covaris focused ultrasonification using a pre-designed program for 250 bp fragmentation (Woburn, MA, USA). Fragmentation performance and size distribution was confirmed with the Bioanalyzer 2100 using the Agilent High Sensitivity DNA Kit.
Sequencing library preparation was performed using the TruSeq DNA Sample Prep Kit according to manufacturer instruction (Illumina, San Diego, CA, USA). Each sample was indexed and subsequently pooled with 10e11 other samples to obtain 7 pooled libraries. Sequence enrichment was performed using the TruSeq Custom Enrichment Trial Kit according to manufacturer instruction (Illumina) to enrich the DNA pool for the sequences of 372 genes commonly altered in cancer (e.g., deletions, somatic mutations, and translocations) using a kit (Illumina) based on the Cancer Gene Census (Futreal et al., 2004) . Following enrichment, the sequencing libraries were evaluated with the Bioanalyzer 2100 using the Agilent High Sensitivity DNA Kit and quantified using the Qubit fluorometer. The final pooled libraries were normalized to 10 nM concentration. Library molecular weight was calculated as the average DNA fragment size multiplied by 650 g mol À1 $bp
À1
. The normalized sequencing libraries were denatured and finally diluted to 10 pM concentration in 1 mL HT1 buffer according to manufacturer instruction (Illumina). DNA cluster generation was performed with a cBot machine (Illumina) and sequencing was performed using HiSeq 1500 NGS sequencing technology according to manufacturer instruction (Illumina For each analyzed sample, the reads were aligned to the hg19 reference genome using Bowtie2 (Langmead and Salzberg, 2012) allowing 1 mismatch. Only reads for which both paired reads were mapped properly were subjected to further analysis. Alignments were converted to the binary alignment/map (BAM) format, restricted to only those which overlapped the specified regions, followed by removing duplicates, sorting, and indexing using SAMtools . Next, an mpileup file was created for each tumor/normal pair and the Varscan2 somatic command was used for calling variants and identifying their somatic status (Germline/ LOH/Somatic) by directly comparing the data at every position of sufficient coverage. The minimum coverage for variant calling was set as 50 whereas the minimum variant frequency for heterozygote calling was 0.01. Varscan2 calls single nucleotide variants (SNVs) as well as indels (short deletions/insertions) but not longer structural variations.
Detection of putative somatic variations in non-paired samples
Paired normal thyroid samples could not be obtained for 14 follicular thyroid tumors. Sample data was processed through mpileup file generation as described above. Next, bcftools was used to create a variant call format (vcf) file. The vcf file for each tumor sample was subjected to the variant effect predictor (VEP) tool from Ensembl (McLaren et al., 2010 ) to obtain functional annotations and database references for obtained variants. The following criteria were utilized for final variant inclusion: called as damaging/deleterious for protein structure by at least one of two used prediction software programs: SIFT (Ng and Henikoff, 2001) and PolyPhen (Sunyaev et al., 2001) ; not found in the Database of Single Nucleotide Polymorphisms (dbSNP) (Sherry et al., 2001) , which contains most germ line variants; or registered in the Catalogue of Somatic Table 1 Clinical information for the tumor samples obtained from patients with follicular thyroid tumors. Sample: sample id; Paired normal; whether a normal thyroid sample was available for the tumor sample; Pair name e name of tumor-normal pair; Patient age: age at time of operation; Histology: tumor histological diagnosis (FTC, FTA, SN: struma nodosa, PDTC); pT; tumor histopathological classification; Metastasis: presence of local or distant metastasis; Recurrence: whether the tumor was a recurrent tumor; Longest dimension (cm); Oncocytic: whether the tumor manifested oncocytic features; Other nodules: whether other nodules were found in the resected thyroid; Invasiveness: whether the tumors were widely (w.in.) or minimally (m.in.) invasive. Mutations in Cancer (COSMIC) (Forbes et al., 2015) database of somatic variants. Following these criteria, detected variants were identified as putatively somatic.
Copy number analysis
Copy number variant (CNV) calling in the samples was performed with the CODEX package (Jiang et al., 2015) to minimize the effects of GC content and amplicon efficiency on the outcome of variant calling. This method is based on coverage distribution in a cross sample design and works well for a tumor-control design.
Detection of chromosomal rearrangements
To detect chromosomal rearrangements using BreakDancer (Chen et al., 2009) , we trimmed the reads to 50 nt, aligned them to the hg19 genome with BWA 0.7.5a (Li and Durbin 2009) using the paired-end mode and default parameters, removed duplicated reads with PicardTools 1.107 (http://broadinstitute.github.io/ picard), and finally applied the BreakDancer-1.1.2 tool. Next, we applied multiple filters to filter out false-positive results. We filtered out rearrangements in which both breakpoints were localized more than 1000 bases from the enriched genes, rearrangements with low coverage (less than 10 reads in each sample), and rearrangements occurring in one or more control samples or similar thereto (both breakpoints within 300 bases near the control rearrangement). The last filter was used because BreakDancer does not recognize the precise localization of the breakpoint.
To detect chromosomal rearrangements by FACTERA (Newman et al., 2014) , we aligned original reads to the hg19 genome with BWA 0.7.5a using paired-end mode and default parameters, removed duplicated reads with PicardTools 1.107, and finally applied the FACTERA v1.4.3 tool. We filtered out rearrangements in which both breakpoints were localized more than 1000 bases from the enriched genes or occurring in one or more control samples.
Finally, we inspected all detected rearrangements manually in Integrative Genomics Viewer (IGV) (Thorvaldsd ottir et al., 2013) to confirm their reliability and filtered out variants that matched normal samples in IGV and those present in the Database of Genomic Variants (DGV) (MacDonald et al., 2014) or in dbSNP (Sherry et al., 2001 ).
NGS data validation
Selected genomic alterations were validated by Sanger sequencing using an Applied Biosystems 3130xl Genetic Analyzer. Methodologic details and primer design are presented in Supplementary Table 1.
Results
Sequencing coverage depth
The data quality obtained during sequencing was very high. We targeted over 5000 gene regions covering large portions of 372 cancer-related genes. The lowest and highest median coverage depths obtained per sample were approximately 300 Â and 3000 Â , respectively. Such high coverage depth should result in very sensitive somatic variant calling. The percentages of bases in our target region with at least 20 Â or 50 Â coverage are presented in Supplementary Fig. 1. 
Detection of somatic mutations, LOH, and indels
Varscan2 software detected 18 high-confidence somatic variants (minimum variant penetration 15%) in 34 tumor-normal thyroid pairs (Table 2) ; these were not found in the remaining 14 samples without a normal pairing.
Numerous LOH events were identified in thyroid tumor samples, some spanning large portions of the gene loci (Fig. 1) . We limited our analysis to LOHs occurring at sites of SNVs with minor allele frequencies (MAF) < 0.1 and putatively affecting protein structure, resulting in the selection of 11 LOHs from the 34 studied thyroid tumor-normal pairs (Supplementary Table 3) .
We also identified numerous indels; however, to ensure high quality data acquisition, only those affecting more than 9% of reads in a certain loci were accepted as valid (Supplementary Table 4) .
Detection of putative somatic variations in non-paired samples
In non-paired tumor material 8 putative somatic variants were found in 4 samples. Of these, 4 are known COSMIC-registered somatic variants, whereas the other variants are not present in any databases, suggesting that these represent novel variants (Supplementary Table 5 ).
Detection of chromosomal rearrangements
We detected 5 rearrangements using BreakDancer (Supplementary Table 6 and 3) rearrangements using FACTERA (Supplementary Table 7 ). The results indicate that there is a rearrangement between COX6C or its pseudogene and DERL2.
We did not detect PAX8-PPARG fusions in our experiment. However, the experiment was not specifically designed for fusion detection and the sensitivity of such analysis may be very low. That is why we cannot draw any conclusions about PAX8-PPARG in our cohort.
CNV results
A number of putative CNVs were found via Codex software analysis. The targeted NGS method is not designed to study CNVs; however, a number of high confidence CNVs were identified (Supplementary Table 8 ).
NGS data validation
All somatic variants selected for validation from the NGS data were confirmed using Sanger sequencing, as described in the Supplementary Materials.
Summary of identified mutations and their classification
A number of putative driver events were discovered, which can be grouped into functional blocks (Fig. 2) . For ready visualization, these were depicted in a scheme according to their integrated function (Fig. 3) . Follicular tumors were divided into high confidence FTCs and low confidence FTCs and FTAs. FTC samples were allocated to the high confidence group if they were defined as widely invasive, with pT higher than 3, had infiltrated lymph nodes, or exhibited co-occurring cancerous tumors in the resected thyroid (Table 1, Fig. 4 ).
Discussion
Follicular thyroid tumors harbor few somatic alterations. Data overview presented in Supplemental Table 2 suggests that mutations, rearrangements and CNV are mutually exclusive. This is reminiscent of data published for papillary thyroid carcinomas by the Cancer Genome Atlas Research Network (1). Accordingly, we were unable to identify somatic alterations in 21/48 studied tumors including two poorly differentiated FTC tumors (T30, T35) (Supplemental Table 2 ). Notably, even though our target enrichment panel was designed to assess coding sequences, we also identified many somatic mutations in the proximal non-coding regions. For example, a JAK3 intronic somatic variant was identified in FTC sample T21 that exhibited a higher penetration than the well-known KRAS gene mutation. Considering tumor clonal evolution, we assume that mutations that provide a growth advantage will be transferred to cell progeny. Thus, the JAK3 variant is unlikely to comprise a passenger mutation. Of the 18 high-confidence somatic SNVs discovered in follicular tumors (Table 2) , over half (10) were non-coding variants in close proximity to exons and in splice sites. Similar non-coding variants might exist for the remaining tumors in regions not covered by this analysis.
The most affected groups of genes in follicular thyroid tumors were (1) oncogenes, (2) transcription factors, (3) epigenetic factors, and (4) protein kinases. Many oncogene alterations were previously identified in these tumors including KRAS, NRAS, and BRAF mutations (Schulten et al., 2013) . Notably, RAS mutation frequency was very low in our patient cohort (4/48 samples); this, together with our unpublished data, suggests that the frequency is lower in the Polish population than elsewhere (Esapa et al., 1999; Jang et al., 2014) . This is unlikely to represent a false negative result, as other somatic exonic variants (including NRAS and KRAS) were readily identified (Tables 1 and 2 ). Two previously undescribed non-coding somatic mutations in the oncogene MDM2, which encodes a key regulator of p53 (Fig. 3) , were found in two FTA samples; one in a splice site that might lead to alternative transcript assembly and the other in an intronic region (Table 2) . A mutation was also found in FLI1, a transcription factor oncogene known to form fusion proteins in sarcomas and leukemias (Zhang et al., 1993) . In the same FTA sample an ALK somatic variant was also found; both variants were located in intronic regions with a very high depth of penetration (over 40%, Table 2 ). The ALK gene locus was also recurrently affected by LOH. Furthermore, we also identified a BRAF mutation in an FTA sample from a patient suffering from a cooccurring PTC tumor. As this is the first report of BRAFV600E occurring in an FTA sample, we cannot exclude the possibility of tumor misclassification owing to a neighboring malignant tumor.
Among the affected transcription factors, MITF, thought to have oncogenic function in skin melanoma, harbored a somatic mutation in one FTC sample and a deletion in another; both were in noncoding regions. The MITF intronic mutation also co-occurred with a KRAS somatic mutation; both exhibited similar penetration Table 2 Somatic mutation selection. Somatic mutations that were selected for Sanger sequencing and positively validated are indicated in bold text. Pair: which tumor-normal pair was detected with mutation; Chrom: chromosome; Position: chromosomal position in the hg19 genome; Gene; in which gene the mutation was detected; Ref: reference allele; Var: alternative allele; Normal_var_freq: percent of alternative reads in the normal thyroid; Tumor_var_freq: percent of alternative reads in the tumor sample; Somatic_p_value: p_value obtained with Varscan2 software; Localization: variant localization in the gene body; Min_coverage: minimal coverage at that SNV position amongst 82 tumor/normal samples used in the study; Median_coverage: median coverage in that SNV position calculated from 82 tumor/normal samples used in the study. Variants selected for Sanger sequencing validation are written with bold font. Fig. 1 . Representation of the primary genes affected by LOH in 6 follicular thyroid tumor samples (T1, T8, T31, T14, T18, and T15). The x-axis represents chromosomal positions within the noted genes wherein LOH was detected by Varscan2; the y-axis is a measure of alternative (grey) and normal/reference (black) allele penetration. Many positions were affected in more than one sample, in that situation sample specific marks, as described in the legend, overlap. LOH, loss of heterozygosity.
( Table 2 ). In addition, the transcriptional repressor gene ZNF331, which is highly expressed in FTAs and a potential fusion partner in adenomas (Rippe et al., 1999) , was found to be mutated in an FTA sample. In FTC samples, new variants not noted in the COSMIC database were identified in the coding regions of the transcription factors FOXO4 and LMO; these are predicted to alter the protein structure of translated genes (Supplementary Table 5 ). PPARG, a common translocation partner of PAX8 in follicular thyroid tumors (Marques et al., 2002) was also altered. Specifically, one FTC and one FTA sample contained a LOH event affecting a SNV site (dbSNP database rs1801282) with an estimated MAF of 0.07 (Supplementary Table 3 ). The normal population frequency of this SNV does not suggest pathogenicity; however a LOH in that position might have a pathogenic effect, as suggested by its recurrence in our study group (two samples), potentially indicating a role in follicular thyroid tumor pathobiology. In addition, a large portion of the PPARG chromosomal region was also partially affected by LOH (Fig. 1) , further suggesting that PPARG might be affected by LOH. Among protein kinases, somatic mutations were identified in JAK3 from the JAK/STAT pathway and in CHEK2, mutations in which represent well-recognized PTC risk factors (W ojcicka et al., 2014) although are rarely considered to be drivers (Cancer Genome Atlas Research Network, 2014) . The well-known growth factor receptor FGFR1 gene was also somatically mutated (Supplementary Table 3 ). Furthermore, LOH was detected at the site of the rare SNP rs4647904 (MAF ¼ 0.007), which is predicted to influence FGFR1 protein structure.
Epigenetic factors, which affect chromatin activation/organization, were among the most affected gene groups in follicular thyroid tumors. Somatic mutations in KMT2A (MLL) and NSD1, which encode histone methyltransferases, were identified. KMT2A was also found to be mutated in PTC tumors (Cancer Genome Atlas Research Network, 2014). Additionally, two genes in the nuclear receptor coactivator family, NCOA1/2, encoding acetyltransferases, were identified. NCOA2 was mutated and NCOA1 harbored LOH at a site wherein a rare (MAF ¼ 0.008) protein-structure affecting genetic variant (as determined by SIFT and PolyPhen) was identified.
Less represented somatically altered functional gene groups were (5) DNA repair (WRN: LOH, BRCA2: missense SNP), (6) endoplasmic reticulum related (KTN1: deletion, DERL2: translocation with COX6C), (7) metabolism related (IDH1: LOH, COX6C: translocation with DERL2, GMPS: missense variant), (8) thyroid hormone receptor activity (TSHR: 2 missense SNPs, 2 LOHs, NR4A3: LOH), and (9) ubiquitination related (CNA in FBXW7 and USP6). Others mutated genes included FCRL4 (immune-response related, Supplementary Table 3), PICALM (endocytosis associated), ARNT (nuclear translocator), xenobiotic metabolism-related, COL1A1 (collagen, structural protein coding), NIN (centrosomal protein coding), NUP98 (nucleoporin), and FIP1L1 (mRNA processinginvolved).
Notably, Table 2 illustrates that most somatic variants (11/18) including the well-known somatic mutations seem to also occur in "normal" thyroid tissue resected from the thyroid lobe. The obtained high sequencing depth suggests that this is not an artifact; for example, the NRAS mutation exhibits penetrations of 34% (315/ 904 reads) and 0.44% (4/689) in tumor (T4) and "normal" thyroid tissue, respectively. These reads arise from independent DNA particles, as PCR duplicates were removed during data analysis. Although we cannot exclude the possibility of cross-contamination, we do not observe neighboring sample cross-contamination elsewhere in our data. These somatic mutations might occur spontaneously in isolated cells across the thyroid, requiring a "second hit" for tumorigenesis; alternately, these might represent migrated tumor cells. Further study is required to resolve these possibilities. Sanger sequencing validation in "normal" thyroid tissue was not possible due to the low penetration of observed mutation (below 1%).
Division of the identified somatic alterations into 3 groups suggests that certain alterations might be specific for well defined, high confidence FTC tumors versus less certain or minimally invasive FTCs; additionally, a high number of somatic alterations were found in our FTA groups (Fig. 4) . Furthermore, newly discovered somatic alterations in genes such as FOXO4, CHEK2, NIN, and GMPS or the COX6C/DERL2 translocation might enhance our understanding of follicular thyroid tumors. Analysis of the frequency of these mutations in a larger cohort will be required to determine their diagnostic utility in the clinic.
Conclusion
The NGS approach used in this study examining a large number of paired patient samples and cancer associated genes allowed us to identify novel somatic alterations that can be considered as putative driver events of follicular thyroid tumors. Validation using a larger follicular thyroid tumors dataset is required to estimate their overall frequency in these tumors. Putative driver events appear quite heterogeneous, suggesting that finding a common driver such as BRAFV600E in PTC is unlikely and that future research in follicular thyroid tumors should focus on rare variants.
